organization · Reporting owner
Versant Venture Capital V (Canada), LP
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | 10% owner | April 24, 2018 | April 26, 2018 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | 10% owner | February 04, 2019 | February 06, 2019 |
| Gritstone bio, Inc.GRTS · Entity 80946 | general partner | October 02, 2018 | October 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date April 24, 2018 · Filed April 26, 2018
Jointly reported with Versant Venture Capital V, L.P., Versant Ventures V, LLC, Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 1,519,505 |
Reported balance
After 2018-04-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-04-24 · Sale · Disposed 20,071 · Balance 1,519,505 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 44,582 |
Reported balance
After 2018-04-24 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-04-24 · Sale · Disposed 589 · Balance 44,582 F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 49,419 |
Reported balance
After 2018-04-24 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-04-24 · Sale · Disposed 653 · Balance 49,419 F6: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee footnote | 115,645 |
Reported balance
After 2018-04-24 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-04-24 · Sale · Disposed 1,528 · Balance 115,645 F8: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F3: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.
F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").
F5: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.
F6: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").
F7: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.
F8: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN").
F9: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.
Crinetics Pharmaceuticals, Inc.
Report date February 04, 2019 · Filed February 06, 2019
Jointly reported with Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Ventures V, LLC, Versant Ventures V (Canada), L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,524,456 |
Reported balance
After 2019-02-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-02-04 · Other · Disposed 445,470 · Balance 2,524,456 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners. F2: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 75,949 |
Reported balance
After 2019-02-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-02-04 · Other · Disposed 13,387 · Balance 75,949 F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners. F4: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 84,161 |
Reported balance
After 2019-02-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-02-04 · Other · Disposed 14,828 · Balance 84,161 F5: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners. F6: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 192,122 |
Reported balance
After 2019-02-04 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2019-02-04 · Other · Disposed 33,903 · Balance 192,122 F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners. F8: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,473 |
Reported balance
After 2019-02-04 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2019-02-04 · Other · Acquired 9,473 · Balance 9,473 F9: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F10: The shares are held VV V. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-02-04 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2019-02-04 · Other · Disposed 9,473 · Balance 0 F11: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F10: The shares are held VV V. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 678 |
Reported balance
After 2019-02-04 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2019-02-04 · Other · Acquired 678 · Balance 678 F12: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F13: The shares are held VV V CAN. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-02-04 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2019-02-04 · Other · Disposed 678 · Balance 0 F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F13: The shares are held VV V CAN. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners.
F2: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.
F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners.
F4: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.
F5: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners.
F6: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.
F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners.
F8: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.
F9: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.
F10: The shares are held VV V.
F11: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.
F12: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.
F13: The shares are held VV V CAN.
F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.
Gritstone bio, Inc.
Report date October 02, 2018 · Filed October 02, 2018
Jointly reported with Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,102,929 |
Reported balance
After 2018-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-10-02 · Conversion · Acquired 3,102,929 · Balance 3,102,929 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: Consists of (I) 2,723,031 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 207,234 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 90.756 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 81,908 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-02 · Conversion · Disposed 2,173,909 · Balance 0 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4: Consists of (I) 1,907,729 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 145,186 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 63,610 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 57,384 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-02 · Conversion · Disposed 929,020 · Balance 0 F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5: Consists of (I) 815,302 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 62,048 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 27,146 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 24,524 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F3: Consists of (I) 2,723,031 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 207,234 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 90.756 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 81,908 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly.
F4: Consists of (I) 1,907,729 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 145,186 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 63,610 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 57,384 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly.
F5: Consists of (I) 815,302 shares held by Versant Venture Capital V, L.P. ("VVC V"), (ii) 62,048 shares held by Versant Venture Capital V (Canada) LP ("VVC CAN"), (iii) 27,146 shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), and (iv) 24,524 shares held by Versant Affiliates Fund V, L.P. ("VAF V"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP"), serves as the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which serves as the sole general partner of VVC CAN and owns no shares directly.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aprea Therapeutics, Inc.
Report date April 09, 2020 · Filed May 20, 2020
Jointly reported with Versant V Luxco S.a r.l., Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Ventures V, LLC, Versant Ventures V (Canada), L.P.
Section 16 reporting ended · disclosed 2020-05-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-04-09 · Other · Disposed 2,519,323 · Balance 0 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration. F2: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco"). F3: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN. |
| Common StockSEC Table I · non-derivative | Direct | 2,210,937 |
Reported balance
After 2020-04-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-04-09 · Other · Acquired 2,210,937 · Balance 2,210,937 F4: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 66,506 |
Reported balance
After 2020-04-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-04-09 · Other · Acquired 66,506 · Balance 66,506 F6: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 73,617 |
Reported balance
After 2020-04-09 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-04-09 · Other · Acquired 73,617 · Balance 73,617 F8: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 168,263 |
Reported balance
After 2020-04-09 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-04-09 · Other · Acquired 168,263 · Balance 168,263 F10: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,437,132 |
Reported balance
After 2020-05-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-05-18 · Other · Disposed 773,805 · Balance 1,437,132 F12: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners. F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 43,231 |
Reported balance
After 2020-05-18 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2020-05-18 · Other · Disposed 23,275 · Balance 43,231 F13: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners. F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 47,823 |
Reported balance
After 2020-05-18 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2020-05-18 · Other · Disposed 25,794 · Balance 47,823 F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners. F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 109,374 |
Reported balance
After 2020-05-18 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2020-05-18 · Other · Disposed 58,889 · Balance 109,374 F15: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners. F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 16,428 |
Reported balance
After 2020-05-18 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2020-05-18 · Other · Acquired 16,428 · Balance 16,428 F16: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F17: The shares are held by VV V. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-18 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2020-05-18 · Other · Disposed 16,428 · Balance 0 F18: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F17: The shares are held by VV V. |
| Common StockSEC Table I · non-derivative | Direct | 1,178 |
Reported balance
After 2020-05-18 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2020-05-18 · Other · Acquired 1,178 · Balance 1,178 F19: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F20: The shares are held by VV V CAN. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-18 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2020-05-18 · Other · Disposed 1,178 · Balance 0 F21: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F20: The shares are held by VV V CAN. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration.
F2: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco").
F3: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN.
F4: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.
F6: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein.
F8: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein.
F10: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein.
F12: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners.
F13: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners.
F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners.
F15: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners.
F16: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.
F17: The shares are held by VV V.
F18: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.
F19: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.
F20: The shares are held by VV V CAN.
F21: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.
Repare Therapeutics Inc.
Report date June 03, 2022 · Filed June 07, 2022
Jointly reported with Versant Ventures V, LLC, Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Venture Capital V, L.P., Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Ventures V (Canada), L.P.
Section 16 reporting ended · disclosed 2022-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 2,344,451 |
Reported balance
After 2022-06-03 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-06-03 · Sale · Disposed 250,000 · Balance 2,344,451 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 1,464,875 |
Reported balance
After 2022-06-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2022-06-03 · Sale · Disposed 438,795 · Balance 1,464,875 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 44,065 |
Reported balance
After 2022-06-03 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2022-06-03 · Sale · Disposed 13,199 · Balance 44,065 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 48,776 |
Reported balance
After 2022-06-03 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2022-06-03 · Sale · Disposed 14,611 · Balance 48,776 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 111,484 |
Reported balance
After 2022-06-03 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2022-06-03 · Sale · Disposed 33,395 · Balance 111,484 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 850,560 |
Reported balance
After 2022-06-06 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2022-06-06 · Other · Disposed 614,315 · Balance 850,560 F7: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners. F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 25,587 |
Reported balance
After 2022-06-06 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2022-06-06 · Other · Disposed 18,478 · Balance 25,587 F10: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners. F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,322 |
Reported balance
After 2022-06-06 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2022-06-06 · Other · Disposed 20,454 · Balance 28,322 F12: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners. F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 64,731 |
Reported balance
After 2022-06-06 transaction · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · 2022-06-06 · Other · Disposed 46,753 · Balance 64,731 F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners. F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 10,099 |
Reported balance
After 2022-06-06 transaction · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · 2022-06-06 · Other · Acquired 10,099 · Balance 10,099 F16: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-06-06 transaction · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · 2022-06-06 · Other · Disposed 10,099 · Balance 0 F18: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 231,211 |
Reported balance
Holding disclosure · report date 2022-06-03 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 231,211 F19: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2022-06-06 transaction · row 12
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 7 · 2022-06-06 · Other · Acquired 132,692 · Balance 132,692 F8: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 9 · 2022-06-06 · Other · Acquired 3,992 · Balance 136,684 F11: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 11 · 2022-06-06 · Other · Acquired 4,419 · Balance 141,103 F13: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 12 · 2022-06-06 · Other · Disposed 141,103 · Balance 0 F14: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F7: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners.
F8: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F10: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners.
F11: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
F12: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners.
F13: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.
F14: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.
F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners.
F16: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).
F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F18: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.
F19: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Turnstone Biologics Corp.
Report date August 08, 2025 · Filed August 12, 2025
Jointly reported with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Vantage II GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II, L.P.
Section 16 reporting ended · disclosed 2025-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V (Canada) LP | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-08-08 · Other · Disposed 207,486 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Ophthalmic Affiliates Fund I, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-08-08 · Other · Disposed 90,888 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Affiliates Fund V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-08-08 · Other · Disposed 82,006 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage II, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-08-08 · Other · Disposed 274,990 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2018 Filed Apr 24, 2018 23:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 497,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010684 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,238,979 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 12 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F21 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F20 · ownership.nature: The shares are held VV V CAN. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 11 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,240 F19 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F20 · ownership.nature: The shares are held VV V CAN. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 17,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 10 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F18 · kind: . Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F17 · ownership.nature: The shares are held VV V. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 17,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 9 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 17,283 F16 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F17 · ownership.nature: The shares are held VV V. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 292,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 8 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F15 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F14 · ownership.nature: The shares are held VV IV. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 292,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 7 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 292,529 F13 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F14 · ownership.nature: The shares are held VV IV. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 26,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 52,987 F11 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners. F12 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 61,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 123,994 F9 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners. F10 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 23,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 47,801 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners. F8 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 814,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,629,204 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners. F6 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 8,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 16,224 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,368,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 2,736,032 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 4,583 | $14.00 | $64,162.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 185,987 F4 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 60,219 | $14.00 | $843,066.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,443,803 F3 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 602 | $14.00 | $8,428.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,334 F2 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 95,596 | $14.00 | $1,338,344.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,104,045 F1 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 5,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 32 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 13,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 31 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 5,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 30 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 29 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 173,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 28 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 27 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 231,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 73,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 26 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 73,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 168,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 25 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 168,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 66,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 24 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 66,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 23 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,210,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-2 Preferred Shares · Derivative | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 22 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-2 Preferred Shares · Derivative | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 21 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,100,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-1 Preferred Shares · Derivative | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 20 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-1 Preferred Shares · Derivative | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 19 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 437,247 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 5,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 18 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 79,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 73,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 17 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 73,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 4,583 | $14.00 | $64,162.00 |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 16 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 185,987 F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 13,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 15 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 181,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 168,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 14 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 168,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 5,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 13 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 71,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 66,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 12 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 66,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 60,219 | $14.00 | $843,066.00 |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 11 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,443,803 F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 10 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,383,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 9 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,210,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 602 | $14.00 | $8,428.00 |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 8 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 24,334 F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 7 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 23,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 6 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 22,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 5 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 2,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 95,596 | $14.00 | $1,338,344.00 |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,104,045 F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,008,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 3,777,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 676,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.